BLTE
Belite Bio, Inc
$149.33
-3.91 (-2.55%)
At close · Jul 10
Market Cap
$5.99B
Shares
40,085,091
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$149.33
Open$152.50
Day$145.57–154.25
52W$59.12–200.00
Avg vol 30d250K
Short int1.3M · 3.3% float · 5.3d
Short vol65%
Last earningsDec 31, 2025
DataApr 2022–Jul 2026
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
Equibles Rating
blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+4%
above
Price vs 50-day avg
+1%
above
RSI (14)
51
neutral
MACD trend
Positive
52-week position
64%
mid-range
Momentum
relative strength
1-month return
+9%
trailing
6-month return
0%
trailing
YTD return
−7%
this year
Relative strength
−9%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $147 › 200d $144 — 50d above 200d
Institutional flow
Distributing
1 of 75 funds reported for Jun 30 · net -21 sh shares
Insider flow
Distributing
Net -$5.5M over 90 days · 100% sells
Short interest
Falling
3.28% of float · ▼ -0.8% MoM · 5.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
75 holders — near 3-yr high, broad support
Squeeze score
58
elevated · 0–100
Fundamentals
EPS growth
−96%
Y/Y
Free cash flow
$-37.1M
Balance sheet
$352.9M
net cash
Quant / Vol
risk profile
Volatility
53%
annualized · 1-yr
Max drawdown
−29%
past year
ATR
5.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Dec 31, 2025
R&D-related activity costs
· next three years
$150M
Commercialization costs
· next three years
$200M – $250M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+4%
Bullish
Price vs 50-day avg
+1%
Bullish
RSI (14)
51
Neutral
MACD trend
Positive
Bullish
52-week position
64%
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $147 › 200d $144 — 50d above 200d
Institutional flow
Distributing
1 of 75 funds reported for Jun 30 · net -21 sh shares
Insider flow
Distributing
Net -$5.5M over 90 days · 100% sells
Short interest
Falling
3.28% of float · ▼ -0.8% MoM · 5.3 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
75 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $59
Now $149 · 64%
52-wk high $200
vs 200-day avg +4%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
BLTE
this stock
Belite Bio, Inc
|
$5.99B | -6.6% | — | — | 3.3% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.67B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| BLTE | +1.8% | +9.3% | -0.2% | -3.0% | -6.7% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +0.5% | +5.2% | -9.3% | -4.1% | -17.4% |